A Flagship VentureLabs Company

T2 Biosystems, Inc.

101 Hartwell Avenue

Lexington, MA  02421

Tel: 781.457.1200


Leadership:
John McDonough
CEO


Website:
www.t2biosystems.com


Information:
info@t2biosystems.com

T2 Biosystems, Inc.

Flagship Partners:  Harry Wilcox
Initial Investment: 
2006
Status: 
Public

T2 Biosystems (NASDAQ: TTOO) is focused on developing innovative diagnostic products to improve patient health. With two FDA authorized products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods.

Harry Wilcox is on the Board of Directors.